| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 09/23/2004 | US20040185507 Isolated monoclonal antibody comprising a light and heavy chain variable of given sequence; diagnosing, treating and preventing prostate/colon cancer and renal carcinoma |
| 09/23/2004 | US20040185460 kits for drug screening by gel-shift assay, western blot, phage-based expression cloning, co-fractionation by chromatography, co-precipitation, cross linking, interaction trap/two hybrid analysis, and enzyme linked immunosorbent assay (ELISA) |
| 09/23/2004 | US20040185439 using polymorphisms to determine susceptibility cancer, osteoporosis, cardiovascular disorders; for drug screening |
| 09/23/2004 | US20040185128 Use of an extract of the root of balloon-flower for preventing and treating a degenerative brain disease or for enhancing memory |
| 09/23/2004 | US20040185122 Selective COX-2 inhibition from edible plant extracts |
| 09/23/2004 | US20040185103 Methods and compositions for enhanced delivery of bioactive molecules |
| 09/23/2004 | US20040185098 Making oral dosage form by forming granules comprising oxycodone hydrochloride, alkyl cellulose and polymethacrylate, and drying said granules |
| 09/23/2004 | US20040185095 Pharmaceutical composition containing oxcarbazepine and having a controlled active substance release |
| 09/23/2004 | US20040185048 Modulation of IL-2- and IL-15-mediated T cell responses |
| 09/23/2004 | US20040185008 Delivery of compounds for the treatment of parkinsons through an inhalation route |
| 09/23/2004 | US20040185007 heating layers containing drugs such as benztropine, pergolide, ropinirole, amantadine and deprenyl on solid supports, to produce vapors, then condensing to aerosols which can be delivered by breathing; drug delivery method and devices |
| 09/23/2004 | US20040185006 Delivery of stimulants through an inhalation route |
| 09/23/2004 | US20040185005 Condensation aerosol as doage forms, is produced by heating a thin layer containing of dolasetron, granisetron or metoclopramide to form vapor, condense into an aerosol; fast producing peak plasma concentrations |
| 09/23/2004 | US20040185004 Delivery of erectile dysfunction drugs through an inhalation route |
| 09/23/2004 | US20040185003 Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route |
| 09/23/2004 | US20040185002 condensation aerosol for delivery of a drug selected from chlordiazepoxide, betahistine, clonidine, testosterone, a conjugated estrogen, an estrogen ester, estradiol, an estradiol ester, ethinyl estradiol, an ethinyl estradiol ester and hyoscyamine |
| 09/23/2004 | US20040185001 Delivery of physiologically active compounds through an inhalation route |
| 09/23/2004 | US20040185000 Delivery of antihistamines through an inhalation route |
| 09/23/2004 | US20040184999 Delivery of anti-migraine compounds through an inhalation route |
| 09/23/2004 | US20040184998 Delivery of drug esters through an inhalation route |
| 09/23/2004 | US20040184997 volatilizing a coating of drug on a solid support, having the surface texture of a metal foil, to a temperature sufficient to produce a heated vapor of drug and condensing the heated vapor to form condensation aerosol particles |
| 09/23/2004 | US20040184996 Delivery of nonsteroidal antiinflammatory drugs through an inhalation route |
| 09/23/2004 | DE10311984A1 Using neutral endopeptidase-associated molecules for treatment, diagnosis, prophylaxis and monitoring of eating and metabolic disorders and dementia, also for drug development |
| 09/23/2004 | DE10311065A1 New 1-(cyclic amino-alkyl)-pyrimidin-2(1H)-one derivatives, are selective dopamine D3 receptor ligands useful for treating CNS disorders, especially schizophrenia or depression |
| 09/23/2004 | CA2519061A1 Substituted aniline derivatives |
| 09/23/2004 | CA2518886A1 Method for treating mild cognitive impairment and for preventing or delaying alzheimer's disease |
| 09/23/2004 | CA2518883A1 Subcutaneous delivery system, process for the preparation of the same and use of the same for the treatment of cholinergic deficient disorders |
| 09/23/2004 | CA2518577A1 Derivation of terminally differentiated dopaminergic neurons from human embryonic stem cells |
| 09/23/2004 | CA2518275A1 Humanized antibodies that recognize beta amyloid peptide |
| 09/23/2004 | CA2518194A1 6-substituted nicotinamide derivatives as opioid receptor antagonists |
| 09/23/2004 | CA2516338A1 Novel compositions containing fentanyl |
| 09/22/2004 | EP1460075A1 Substituted 8-Pyridinyl-6,7,8,9-Tetrahydropyrimido[1,2-a]Pyrimidin-4-one and 8-Phenyl-6-7,8,9-Tetrahydropyrimido[1,2-a]Pyrimidin-4-one derivatives |
| 09/22/2004 | EP1460073A1 Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators |
| 09/22/2004 | EP1460070A1 Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators |
| 09/22/2004 | EP1460069A1 Substituted cyclohexyl and piperidinyl derivatives as melanocortin-4 receptor modulators |
| 09/22/2004 | EP1460066A1 Piperazine compounds |
| 09/22/2004 | EP1460062A1 Nitrogenous cyclic ketone derivative, process for producing the same, and use |
| 09/22/2004 | EP1459765A1 6-fluorobicyclo 3.1.0 hexane derivatives |
| 09/22/2004 | EP1459764A1 Remedies for mild recognition deflict |
| 09/22/2004 | EP1459759A1 Drug mobilizing pluripotent stem cells from tissue into peripheral blood |
| 09/22/2004 | EP1459751A1 (S,S)-reboxetine for treating migraine headaches |
| 09/22/2004 | EP1459750A1 (S,S)-reboxetine for treating fibromyalgia and other somatoform disorders |
| 09/22/2004 | EP1459749A1 (S,S)-reboxetine for treating incontinence |
| 09/22/2004 | EP1459748A1 (S,S)-reboxetine for treating peripheral neuropathy |
| 09/22/2004 | EP1459746A1 The use of vitamin B6 to mitigate visual field defects associated with the use of GABAergic drugs in mammals |
| 09/22/2004 | EP1459063A2 Screening method for compounds that modulate neuronal activity |
| 09/22/2004 | EP1458888A2 Methods of treating psychosis and schizophrenia based on polymorphisms in the cntf gene |
| 09/22/2004 | EP1458865A2 Human vanilloid receptor protein and polynucleotide sequence encoding same |
| 09/22/2004 | EP1458754A2 Novel death associated proteins of the thap family and related par4 pathways involved in apoptosis control |
| 09/22/2004 | EP1458748A2 Apoptotically active peptides |
| 09/22/2004 | EP1458745A2 SUBSTITUTED AMINO CARBOXAMIDES FOR THE TREATMENT OF ALZHEIMER'S DISEASE |
| 09/22/2004 | EP1458741A2 Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid |
| 09/22/2004 | EP1458723A1 Fused heterocyclic succinimidecompounds and analogs thereof, modulators of nuclear hormone receptor function |
| 09/22/2004 | EP1458722A1 Pyrrolopyrimidines as phosphodiesterase vii inhibitors |
| 09/22/2004 | EP1458721A1 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino 4,5-b]indole-1-carboxamide derivatives, their preparation and therapeutic use |
| 09/22/2004 | EP1458718A1 Quinolinones as prostaglandin receptor ligands |
| 09/22/2004 | EP1458717A1 Aroyl pyridinones |
| 09/22/2004 | EP1458716A1 Bicyclic n-arylamides |
| 09/22/2004 | EP1458714A1 3,4-dihydro-1h-isoquinoloin-2-yl-derivatives |
| 09/22/2004 | EP1458712A2 Novel compounds |
| 09/22/2004 | EP1458711A1 Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer s disease and conditions associated with glycogen synthase kinase-3 |
| 09/22/2004 | EP1458710A1 Heteroaryl substituted pyrrole modulators of metabotropic glutamate receptor-5 |
| 09/22/2004 | EP1458708A2 Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5 |
| 09/22/2004 | EP1458707A2 New compounds |
| 09/22/2004 | EP1458706A1 Diaryl 1,2,4-triazole derivatives as a highly selective cyclooxygenase-2 inhibitor |
| 09/22/2004 | EP1458704A1 Aminoindane derivatives as serotonin and norepinephrine uptake inhibitors |
| 09/22/2004 | EP1458703A1 Isochroman compounds for treatment of cns disorders |
| 09/22/2004 | EP1458691A2 Benzodiazepine derivatives, preparation thereof and use thereof |
| 09/22/2004 | EP1458690A1 5,6-diaryl-pyrazine-2-amide derivatives as cb1 antagonists |
| 09/22/2004 | EP1458689A1 Aryloxyphenyl and arylsulfanylphenyl derivatives |
| 09/22/2004 | EP1458688A1 Quinazolinone derivative |
| 09/22/2004 | EP1458687A2 Pyrimidine compounds |
| 09/22/2004 | EP1458684A2 Therapeutic heterocycles |
| 09/22/2004 | EP1458680A1 Prodrugs to d-prolines |
| 09/22/2004 | EP1458679A2 Pyrrolidine derivatives as prostaglandin modulators |
| 09/22/2004 | EP1458676A2 Compounds for the treatment of inflammatory disorders |
| 09/22/2004 | EP1458669A1 Neuorologically-active compounds |
| 09/22/2004 | EP1458413A2 Pharmaceutical compositions based on azetidine derivatives |
| 09/22/2004 | EP1458411A2 Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders |
| 09/22/2004 | EP1458399A1 Pregnane steroids for use in the treatment of cns disorders |
| 09/22/2004 | EP1458397A1 Use of therapeutic dosages for nitric oxide donors which do not significantly lower blood pressure or pulmonary artery pressure |
| 09/22/2004 | EP1458395A1 New use |
| 09/22/2004 | EP1458394A1 Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer s disease and conditions associated with glycogen synthase kinase-3 |
| 09/22/2004 | EP1458388A1 A liquid pharmaceutical formulation comprising nicotine for the administration to the oral cavity |
| 09/22/2004 | EP1458386A1 Aroyl pyrrole heteroeryl and methanols useful for treating a central nervous system disorder |
| 09/22/2004 | EP1458385A2 Heteroaryl substituted imidazole modulators of metabotropic glutamate receptor-5 |
| 09/22/2004 | EP1458383A2 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 |
| 09/22/2004 | EP1458379A1 Hydroxyphenyl-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| 09/22/2004 | EP1458378A1 Amino acid derivatives useful for the treatment of alzheimer's disease |
| 09/22/2004 | EP1458375A2 Compositions for decreasing activity of hormone-sensitive lipase |
| 09/22/2004 | EP1458374A2 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase |
| 09/22/2004 | EP1458368A1 Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure |
| 09/22/2004 | EP1458367A1 Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
| 09/22/2004 | EP1458355A2 Aqueous based pharmaceutical formulations of water-soluble prodrugs of propofol |
| 09/22/2004 | EP1458353A1 Formulation dosage form for the controlled delivery of ther apeutic agents |
| 09/22/2004 | EP1458337A1 Stable surfactant compositions for suspending components |
| 09/22/2004 | EP1458234A1 Disruption of the prostaglandin e synthase 2 gene |
| 09/22/2004 | EP1350104A4 Presenilin enhancers |
| 09/22/2004 | EP1274709B1 Salts of bicyclic, n-acylated imidazo-3-amines and imidazo-5-amines |
| 09/22/2004 | EP1265904B1 Novel positive allosteric ampa receptor modulators (paarm), method for the production and use thereof as medicaments |